{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:57:16Z","timestamp":1793159836157,"version":"4.5.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01319-6","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:43:20Z","timestamp":1753872200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes"],"prefix":"10.1007","volume":"27","author":[{"given":"Kyle","family":"Sheth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Porterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Wadhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"Suppl 1","key":"1319_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321. https:\/\/doi.org\/10.1111\/dom.13129.","journal-title":"Diabetes Obes Metab"},{"key":"1319_CR2","doi-asserted-by":"publisher","unstructured":"Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc. 2024;64(1):133-8. https:\/\/doi.org\/10.1016\/j.japh.2023.10.002","DOI":"10.1016\/j.japh.2023.10.002"},{"issue":"5","key":"1319_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1517\/14740330903081725","volume":"8","author":"J Mitri","year":"2009","unstructured":"Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8(5):573\u201384. https:\/\/doi.org\/10.1517\/14740330903081725.","journal-title":"Expert Opin Drug Saf"},{"key":"1319_CR4","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metab"},{"issue":"3","key":"1319_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"3","key":"1319_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X, et al. The Weight-loss effect of GLP-1RAs Glucagon-Like Peptide-1 receptor agonists in Non-diabetic individuals with overweight or obesity: A systematic review with Meta-Analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr. 2023;118(3):614\u201326. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.017.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"1319_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"4","key":"1319_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"10157","key":"1319_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X.","journal-title":"Lancet"},{"issue":"10193","key":"1319_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"19","key":"1319_CR11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"1319_CR12","doi-asserted-by":"publisher","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, Ruyeras J, Aparece JP, Bantayan NRB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100679.","journal-title":"Am J Prev Cardiol"},{"issue":"10019","key":"1319_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s0140-6736(15)00803-x","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(15)00803-x.","journal-title":"Lancet"},{"issue":"1","key":"1319_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","volume":"53","author":"J Kumar","year":"2021","unstructured":"Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021;53(1):44\u201351. https:\/\/doi.org\/10.1016\/j.dld.2020.08.021.","journal-title":"Dig Liver Dis"},{"issue":"7","key":"1319_CR15","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058\u201366. https:\/\/doi.org\/10.1038\/s41591-024-03015-5.","journal-title":"Nat Med"},{"issue":"4","key":"1319_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","volume":"103","author":"KR Tuttle","year":"2023","unstructured":"Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023;103(4):772\u201381. https:\/\/doi.org\/10.1016\/j.kint.2022.12.028.","journal-title":"Kidney Int"},{"issue":"13","key":"1319_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","journal-title":"N Engl J Med"},{"issue":"24","key":"1319_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"1319_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic Dysfunction-Associated steatohepatitis. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"12","key":"1319_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A Placebo-Controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"issue":"3","key":"1319_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951\u201362. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med"},{"key":"1319_CR22","unstructured":"Food and Drug Administration. FDA News Release. https:\/\/www.fda.gov\/. Accessed 31 March 2025."},{"issue":"5","key":"1319_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/8755122517711958","volume":"33","author":"JS Newsome","year":"2017","unstructured":"Newsome JS, Lixisenatide. A new option for managing type 2 diabetes. J Pharm Technol. 2017;33(5):195\u2013203. https:\/\/doi.org\/10.1177\/8755122517711958.","journal-title":"J Pharm Technol"},{"issue":"2","key":"1319_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"5","key":"1319_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14656566.2023.2192865","volume":"24","author":"RA Lafferty","year":"2023","unstructured":"Lafferty RA, FP R, Irwin N. GLP-1\/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opin Pharmacother. 2023;24(5):587\u201397. https:\/\/doi.org\/10.1080\/14656566.2023.2192865.","journal-title":"Expert Opin Pharmacother"},{"key":"1319_CR26","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410.","journal-title":"BMJ"},{"key":"1319_CR27","unstructured":"Brett AS. Another GLP-1 Receptor Agonist for Weight Management. 2021. https:\/\/www.jwatch.org\/na54359\/2021\/12\/27\/another-glp-1-receptor-agonist-weight-management. Accessed March 31, 2025."},{"key":"1319_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","volume":"92","author":"YC Chooi","year":"2019","unstructured":"Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6\u201310. https:\/\/doi.org\/10.1016\/j.metabol.2018.09.005.","journal-title":"Metabolism"},{"key":"1319_CR29","unstructured":"World Health Organization: Overweight and Obesity. 2024. https:\/\/www.who.int\/. Accessed March 31, 2025."},{"key":"1319_CR30","unstructured":"Panuganti KK, Nguyen M, Kshirsagar RK, Obesity. StatPearls. Treasure Island, FL; 2025."},{"key":"1319_CR31","unstructured":"Fair Health: Obesity and GLP-1 Drugs: A Claims-Based Analysis. 2025. https:\/\/s3.amazonaws.com\/media2.fairhealth.org\/whitepaper\/asset\/Obesity%20and%20GLP-1%20Drugs%20-%20A%20FAIR%20Health%20White%20Paper.pdf. Accessed 16 June 2025."},{"issue":"1","key":"1319_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/jama.2024.10333","volume":"332","author":"E Harris","year":"2024","unstructured":"Harris E, Poll. Roughly 12% of US adults have used a GLP-1 drug, even if unaffordable. JAMA. 2024;332(1):8. https:\/\/doi.org\/10.1001\/jama.2024.10333.","journal-title":"JAMA"},{"issue":"5","key":"1319_CR33","doi-asserted-by":"publisher","first-page":"E981","DOI":"10.1152\/ajpendo.1997.273.5.E981","volume":"273","author":"MA Nauck","year":"1997","unstructured":"Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 Inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5):E981\u20138. https:\/\/doi.org\/10.1152\/ajpendo.1997.273.5.E981.","journal-title":"Am J Physiol"},{"issue":"6","key":"1319_CR34","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1210\/jc.2003-030049","volume":"88","author":"JJ Meier","year":"2003","unstructured":"Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719\u201325. https:\/\/doi.org\/10.1210\/jc.2003-030049.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1319_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","volume":"15","author":"M Shah","year":"2014","unstructured":"Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181\u20137. https:\/\/doi.org\/10.1007\/s11154-014-9289-5.","journal-title":"Rev Endocr Metab Disord"},{"key":"1319_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/DMSO.S387116","volume":"16","author":"M Aldawsari","year":"2023","unstructured":"Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes. 2023;16:575\u201395. https:\/\/doi.org\/10.2147\/DMSO.S387116.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"1319_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/s2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392\u2013406. https:\/\/doi.org\/10.1016\/s2213-8587(20)30074-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1319_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s2213-8587(18)30024-x","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386. https:\/\/doi.org\/10.1016\/s2213-8587(18)30024-x.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1319_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"1319_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","journal-title":"N Engl J Med"},{"issue":"10","key":"1319_CR41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40618-019-01047-0","volume":"42","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. J Endocrinol Invest. 2019;42(10):1165\u20139. https:\/\/doi.org\/10.1007\/s40618-019-01047-0.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1319_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. https:\/\/doi.org\/10.1186\/s12933-021-01366-8.","journal-title":"Cardiovasc Diabetol"},{"key":"1319_CR43","unstructured":"Mattina C. FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight. 2024. https:\/\/www.ajmc.com. Accessed March 31, 2025."},{"issue":"6","key":"1319_CR44","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/dom.15529","volume":"26","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Lumbang GNO, Gaid DRM, Cruz LLA, Magalong JV, Bantayan NRB, et al. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. Diabetes Obes Metab. 2024;26(6):2209\u201328. https:\/\/doi.org\/10.1111\/dom.15529.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1319_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2337\/ds20-0072","volume":"34","author":"TK Thethi","year":"2021","unstructured":"Thethi TK, Bilal A, Pratley RE. Cardiovascular outcomes trials of Incretin-Based therapies. Diabetes Spectr. 2021;34(3):217\u201324. https:\/\/doi.org\/10.2337\/ds20-0072.","journal-title":"Diabetes Spectr"},{"key":"1319_CR46","doi-asserted-by":"publisher","first-page":"1007980","DOI":"10.3389\/fendo.2022.1007980","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang B, Wang R, Ye H, Wang Y, Wang L, et al. Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis. Front Endocrinol (Lausanne). 2022;13:1007980. https:\/\/doi.org\/10.3389\/fendo.2022.1007980.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1319_CR47","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with Glucagon-Like Peptide-1 receptor agonists and dipeptidyl Peptidase-4 inhibitors. Circulation. 2017;136(9):849\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028136.","journal-title":"Circulation"},{"issue":"3","key":"1319_CR48","doi-asserted-by":"publisher","first-page":"e1267","DOI":"10.1210\/clinem\/dgad572","volume":"109","author":"EJ Meyer","year":"2024","unstructured":"Meyer EJ, Wittert GA. Approach the patient with obstructive sleep apnea and obesity. J Clin Endocrinol Metabolism. 2024;109(3):e1267\u201379. https:\/\/doi.org\/10.1210\/clinem\/dgad572.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1319_CR49","doi-asserted-by":"publisher","unstructured":"Le KDR, Le K, Foo F. The impact of Glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: A scoping review. Pharm (Basel). 2024;12(1). https:\/\/doi.org\/10.3390\/pharmacy12010011.","DOI":"10.3390\/pharmacy12010011"},{"key":"1319_CR50","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am J Prev Cardiol. 2023;14:100502. https:\/\/doi.org\/10.1016\/j.ajpc.2023.100502.","journal-title":"Am J Prev Cardiol"},{"issue":"17","key":"1319_CR51","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/circulationaha.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of Glucagon-Like peptide receptor agonists and Sodium-Glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022\u201331. https:\/\/doi.org\/10.1161\/circulationaha.118.038868.","journal-title":"Circulation"},{"issue":"1","key":"1319_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Gorriz JL, Soler MJ, Cigarr\u00e1n Guldris S, Cruzado JM, Puchades MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31(1):278\u201385. https:\/\/doi.org\/10.1038\/s41591-024-03327-6.","journal-title":"Nat Med"},{"issue":"3","key":"1319_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated steatotic liver disease (MASLD): A State-of-the-Art review. J Obes Metab Syndr. 2023;32(3):197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052.","journal-title":"J Obes Metab Syndr"},{"issue":"5","key":"1319_CR54","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/hep.0000000000000323.","journal-title":"Hepatology"},{"issue":"4","key":"1319_CR55","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s40501-024-00331-y","volume":"11","author":"S Tempia Valenta","year":"2024","unstructured":"Tempia Valenta S, Nicastri A, Perazza F, Marcolini F, Beghelli V, Atti AR, et al. The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: A systematic review. Curr Treat Options Psychiatry. 2024;11(4):310\u201357. https:\/\/doi.org\/10.1007\/s40501-024-00331-y.","journal-title":"Curr Treat Options Psychiatry"},{"issue":"4","key":"1319_CR56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","volume":"179","author":"MK Klausen","year":"2022","unstructured":"Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022;179(4):625\u201341. https:\/\/doi.org\/10.1111\/bph.15677.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1319_CR57","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4(10):718\u201331. https:\/\/doi.org\/10.1016\/j.molmet.2015.07.008.","journal-title":"Mol Metab"},{"issue":"1","key":"1319_CR58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neuropharm.2008.07.011","volume":"56","author":"PW Kalivas","year":"2009","unstructured":"Kalivas PW, Lalumiere RT, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology. 2009;56(1):169\u2013. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.07.011. \u200973.","journal-title":"Neuropharmacology"},{"key":"1319_CR59","doi-asserted-by":"publisher","first-page":"112424","DOI":"10.1016\/j.drugalcdep.2024.112424","volume":"264","author":"S Martinelli","year":"2024","unstructured":"Martinelli S, Mazzotta A, Longaroni M, Petrucciani N. Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials. Drug Alcohol Depend. 2024;264:112424. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112424.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1319_CR60","doi-asserted-by":"publisher","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","volume":"13","author":"F Quddos","year":"2023","unstructured":"Quddos F, Hubshman Z, Tegge A, Sane D, Marti E, Kablinger AS, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13(1):20998. https:\/\/doi.org\/10.1038\/s41598-023-48267-2.","journal-title":"Sci Rep"},{"key":"1319_CR61","doi-asserted-by":"publisher","unstructured":"Richards JR, Dorand MF, Royal K, Mnajjed L, Paszkowiak M, Simmons WK. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: A case series. J Clin Psychiatry. 2023;85(1). https:\/\/doi.org\/10.4088\/JCP.23m15068.","DOI":"10.4088\/JCP.23m15068"},{"key":"1319_CR62","doi-asserted-by":"publisher","first-page":"101865","DOI":"10.1016\/j.eclinm.2023.101865","volume":"57","author":"S Lengsfeld","year":"2023","unstructured":"Lengsfeld S, Burkard T, Meienberg A, Jeanloz N, Vukajlovic T, Bologna K, et al. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 2023;57:101865. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101865.","journal-title":"EClinicalMedicine"},{"key":"1319_CR63","doi-asserted-by":"publisher","unstructured":"Probst L, Monnerat S, Vogt DR, Lengsfeld S, Burkard T, Meienberg A, et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023;8(22). https:\/\/doi.org\/10.1172\/jci.insight.170419.","DOI":"10.1172\/jci.insight.170419"},{"key":"1319_CR64","doi-asserted-by":"publisher","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","volume":"221","author":"GA Angarita","year":"2021","unstructured":"Angarita GA, Matuskey D, Pittman B, Costeines JL, Potenza MN, Jastreboff AM, et al. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug Alcohol Depend. 2021;221:108614. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108614.","journal-title":"Drug Alcohol Depend"},{"key":"1319_CR65","doi-asserted-by":"publisher","unstructured":"Klausen MK, Jensen ME, M\u00f8ller M, Le Dous N, Jensen A, Zeeman VA, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19). https:\/\/doi.org\/10.1172\/jci.insight.159863.","DOI":"10.1172\/jci.insight.159863"},{"key":"1319_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntab066","author":"L Yammine","year":"2021","unstructured":"Yammine L, Green CE, Kosten TR, de Dios C, Suchting R, Lane SD, et al. Nicotine Tob Res. 2021;23(10):1682\u201390. https:\/\/doi.org\/10.1093\/ntr\/ntab066. Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial."},{"key":"1319_CR67","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.eclinm.2024.102726","volume":"74","author":"R De Giorgi","year":"2024","unstructured":"De Giorgi R, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ, et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. EClinicalMedicine. 2024;74:102726. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102726.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1319_CR68","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","volume":"25","author":"W Halloum","year":"2024","unstructured":"Halloum W, Dughem YA, Beier D, Pellesi L. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J Headache Pain. 2024;25(1):112. https:\/\/doi.org\/10.1186\/s10194-024-01821-3.","journal-title":"J Headache Pain"},{"key":"1319_CR69","doi-asserted-by":"publisher","unstructured":"Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9(404). https:\/\/doi.org\/10.1126\/scitranslmed.aan0972.","DOI":"10.1126\/scitranslmed.aan0972"},{"issue":"1","key":"1319_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-023-01631-z","volume":"24","author":"N Krajnc","year":"2023","unstructured":"Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M, et al. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023;24(1):89. https:\/\/doi.org\/10.1186\/s10194-023-01631-z.","journal-title":"J Headache Pain"},{"issue":"5","key":"1319_CR71","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/brain\/awad003","volume":"146","author":"JL Mitchell","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821\u201330. https:\/\/doi.org\/10.1093\/brain\/awad003.","journal-title":"Brain"},{"issue":"3","key":"1319_CR72","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","volume":"67","author":"R Dhanapalaratnam","year":"2024","unstructured":"Dhanapalaratnam R, Issar T, Lee ATK, Poynten AM, Milner KL, Kwai NCG, et al. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia. 2024;67(3):561\u20136. https:\/\/doi.org\/10.1007\/s00125-023-06072-6.","journal-title":"Diabetologia"},{"issue":"12","key":"1319_CR73","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMoa2200436","volume":"387","author":"DM Nathan","year":"2022","unstructured":"Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, et al. Glycemia reduction in type 2 Diabetes - Microvascular and cardiovascular outcomes. N Engl J Med. 2022;387(12):1075\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2200436.","journal-title":"N Engl J Med"},{"issue":"8","key":"1319_CR74","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jdiacomp.2015.07.013","volume":"29","author":"M Jaiswal","year":"2015","unstructured":"Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, Feldman EL, et al. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications. 2015;29(8):1287\u201394. https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.07.013.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"1319_CR75","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","volume":"39","author":"Y Han","year":"2019","unstructured":"Han Y, Li Y, He B. GLP-1 receptor agonists versus Metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019;39(2):332\u201342. https:\/\/doi.org\/10.1016\/j.rbmo.2019.04.017.","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"1319_CR76","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00404-022-06700-3","volume":"306","author":"R Li","year":"2022","unstructured":"Li R, Mai T, Zheng S, Zhang Y. Effect of Metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Arch Gynecol Obstet. 2022;306(5):1711\u201321. https:\/\/doi.org\/10.1007\/s00404-022-06700-3.","journal-title":"Arch Gynecol Obstet"},{"issue":"11","key":"1319_CR77","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/jbmr.3214","volume":"32","author":"KC Johnson","year":"2017","unstructured":"Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP, et al. The effect of intentional weight loss on fracture risk in persons with diabetes: results from the look AHEAD randomized clinical trial. J Bone Min Res. 2017;32(11):2278\u201387. https:\/\/doi.org\/10.1002\/jbmr.3214.","journal-title":"J Bone Min Res"},{"key":"1319_CR78","doi-asserted-by":"publisher","unstructured":"Wikarek A, Grabarczyk M, Klimek K, Janoska-Gawro\u0144ska A, Suchodolska M, Holecki M. Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures. Med (Kaunas). 2024;60(3). https:\/\/doi.org\/10.3390\/medicina60030393.","DOI":"10.3390\/medicina60030393"},{"issue":"2","key":"1319_CR79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14740338.2015.987122","volume":"14","author":"A Consoli","year":"2015","unstructured":"Consoli A, Formoso G. Potential side effects to GLP-1 agonists: Understanding their safety and tolerability. Exp Opin Drug Saf. 2015;14(2):207\u201318. https:\/\/doi.org\/10.1517\/14740338.2015.987122.","journal-title":"Exp Opin Drug Saf"},{"key":"1319_CR80","doi-asserted-by":"publisher","first-page":"1416985","DOI":"10.3389\/fphar.2024.1416985","volume":"15","author":"L He","year":"2024","unstructured":"He L, Li Q, Yang Y, Li J, Luo W, Huang Y, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Front Pharmacol. 2024;15:1416985. https:\/\/doi.org\/10.3389\/fphar.2024.1416985.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1319_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/thy.2024.0387","volume":"35","author":"SM Baxter","year":"2025","unstructured":"Baxter SM, Lund LC, Andersen JH, Brix TH, Heged\u00fcs L, Hsieh MH, et al. Glucagon-Like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study. Thyroid. 2025;35(1):69\u201378. https:\/\/doi.org\/10.1089\/thy.2024.0387.","journal-title":"Thyroid"},{"issue":"2","key":"1319_CR82","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2022","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid Cancer. Diabetes Care. 2022;46(2):384\u201390. https:\/\/doi.org\/10.2337\/dc22-1148.","journal-title":"Diabetes Care"},{"key":"1319_CR83","doi-asserted-by":"publisher","first-page":"924168","DOI":"10.1155\/2012\/924168","volume":"2012","author":"WY Chiu","year":"2012","unstructured":"Chiu WY, Shih SR, Tseng CH. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res. 2012;2012:924168. https:\/\/doi.org\/10.1155\/2012\/924168.","journal-title":"Exp Diabetes Res"},{"issue":"8","key":"1319_CR84","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr., et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1319_CR85","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","volume":"68","author":"I Kapoor","year":"2023","unstructured":"Kapoor I, Sarvepalli SM, D\u2019Alessio D, Grewal DS, Hadziahmetovic M. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Surv Ophthalmol. 2023;68(6):1071\u201383. https:\/\/doi.org\/10.1016\/j.survophthal.2023.07.002.","journal-title":"Surv Ophthalmol"},{"key":"1319_CR86","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.1455","author":"R Shor","year":"2025","unstructured":"Shor R, Mihalache A, Noori A, Shor R, Kohly RP, Popovic MM, et al. Glucagon-Like Peptide-1 receptor agonists and risk of neovascular Age-Related macular degeneration. JAMA Ophthalmol. 2025. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.1455.","journal-title":"JAMA Ophthalmol"},{"key":"1319_CR87","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16318","author":"RM Radwan","year":"2025","unstructured":"Radwan RM, Lee YA, Kotecha P, Wright DR, Hernandez I, Ramon R, et al. Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.16318.","journal-title":"Diabetes Obes Metab"},{"key":"1319_CR88","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018. 2020. Accessed 23 June 2025. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db360.htm"},{"key":"1319_CR89","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.diabres.2018.06.016","volume":"143","author":"H Kang","year":"2018","unstructured":"Kang H, Lobo JM, Kim S, Sohn MW. Cost-related medication non-adherence among U.S. Adults with diabetes. Diabetes Res Clin Pract. 2018;143:24\u201333. https:\/\/doi.org\/10.1016\/j.diabres.2018.06.016.","journal-title":"Diabetes Res Clin Pract"},{"key":"1319_CR90","doi-asserted-by":"publisher","unstructured":"Jeyakumar Y, Richardson L, Sarma S, Retnakaran R, Kramer CK. Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps. BMJ Glob Health. 2024;9(11). https:\/\/doi.org\/10.1136\/bmjgh-2024-017177.","DOI":"10.1136\/bmjgh-2024-017177"},{"key":"1319_CR91","unstructured":"Food and Drug Administration: FDA-Approved Drugs. 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 24 March 2025."},{"key":"1319_CR92","unstructured":"Medicaid: National Average Drug Acquisition Cost (NADAC). 2024. https:\/\/data.medicaid.gov\/dataset\/99315a95-37ac-4eee-946a-3c523b4c481e. Accessed March 3, 2025."},{"key":"1319_CR93","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice C","year":"2024","unstructured":"American Diabetes Association Professional Practice C. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142025. Diabetes Care. 2024;48:S181\u2013206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"issue":"3\u20134","key":"1319_CR94","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3\u20134):202\u201330. https:\/\/doi.org\/10.1900\/RDS.2014.11.202.","journal-title":"Rev Diabet Stud"},{"issue":"3","key":"1319_CR95","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","volume":"16","author":"R Shetty","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab Syndr. 2022;16(3):102427. https:\/\/doi.org\/10.1016\/j.dsx.2022.102427.","journal-title":"Diabetes Metab Syndr"},{"key":"1319_CR96","doi-asserted-by":"publisher","first-page":"645507","DOI":"10.3389\/fendo.2021.645507","volume":"12","author":"B Gallwitz","year":"2021","unstructured":"Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne). 2021;12:645507. https:\/\/doi.org\/10.3389\/fendo.2021.645507.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1319_CR97","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23(9):2116\u201324. https:\/\/doi.org\/10.1111\/dom.14451.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1319_CR98","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54(9):1150\u201361. https:\/\/doi.org\/10.1111\/apt.16608.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1319_CR99","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10313","key":"1319_CR100","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)02188-7.","journal-title":"Lancet"},{"issue":"12","key":"1319_CR101","doi-asserted-by":"publisher","first-page":"e76007","DOI":"10.7759\/cureus.76007","volume":"16","author":"N Mando","year":"2024","unstructured":"Mando N, Thomson E, Fowler M, Short L, Gillen N. Acute pancreatitis caused by Tirzepatide. Cureus. 2024;16(12):e76007. https:\/\/doi.org\/10.7759\/cureus.76007.","journal-title":"Cureus"},{"issue":"4","key":"1319_CR102","doi-asserted-by":"publisher","first-page":"bvad016","DOI":"10.1210\/jendso\/bvad016","volume":"7","author":"R Mishra","year":"2023","unstructured":"Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, et al. Adverse events related to Tirzepatide. J Endocr Soc. 2023;7(4):bvad016. https:\/\/doi.org\/10.1210\/jendso\/bvad016.","journal-title":"J Endocr Soc"},{"issue":"4","key":"1319_CR103","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic Dysfunction-Associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"6","key":"1319_CR104","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A. Effect of Tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(22)00070-5.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01319-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01319-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01319-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T07:04:49Z","timestamp":1753945489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01319-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01319-6","relation":{"references":[{"id-type":"doi","id":"10.1093\/ntr\/ntab066","asserted-by":"subject"}]},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"3 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review of previously published studies; therefore, ethical approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The Section Editors for the Topical Collection Coronary Heart Disease are Salim Virani and Mahmoud Al-Rifai. Please note that Section Editor, Salim Virani was not involved in the editorial process of this article as he is a co-author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Topical Collection on Coronary Heart Disease"}}],"article-number":"76"}}